ESMO

Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin

Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy

A new anti cancer drug sevabertinib, that targets mutated HER2, has proved effective in the SOHO-01 study among patients wiith HER2 mutated non small cell lung cancer. It has now been reported in the

A big step forwards in the management of muscle invasive bladder cancer in which platinum cannot be used has been taken in the KEYNOTE-905 study of perioperative antibody drug conjugate thereapy with

A Chinese ADC and a western ADC slugged it out at the 2025 ESMO held in Berlin.

Tarlatamab, a bi-specific T-cell engager drug added to innitial immunochemotherapy brought encouraging initial survival outcomes in the DeLLphi-303 reported at the European Society for Medical Oncolog

John P. Crown MD MBA: ESMO 2025, Berlin: Adjuvant Ribociclib Brought Longer Freedom from Metastases for Patients with HR+/HER2- Early Breast Cancer: NATALEE Five Year Outcomes

Javier Cortés tells his findings from ASCENT-03 as reported to ESMO 2025 in Berlin with antibody drug conjugate as initial therapy for TNBC in patients testing negative for PD-1/PD-L1

MUNICH—A leading European oncologist acknowledged the impressive life-extending potential of new drug combinations for metastatic renal cell carcinoma discussed at the 2018 annual congress of the Euro

MUNICH— A doubling of progression free survival (PFS) and objective response rate (ORR) was observed in patients who had their previously untreated advanced renal cell cancer (RCC) treated with a comb

MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK ge

MUNICH—The role of poly ADP ribose polymerase (PARP) inhibitors for treating newly diagnosed advanced ovarian cancer was under review at the 2018 annual congress of the European Society for Medical On

BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled

MUNICH— Immunotherapy with the anti programmed death ligand 1 (PD-L1) checkpoint inhibitor atezolizumab in combination with nab-paclitaxel chemotherapy prolonged progression-free survival (PFS) among

MUNICH—A combination of the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib plus fulvestrant significantly extended progression free survival (PFS) compared to placebo plus fulvestr

MUNICH—Patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer who were treated with a combination of the cyclin dependent kina

MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSC

BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) w

Audio Journal of Oncology, January 2, 2017 COPENHAGEN—Patients with metastatic non-small cell lung cancers (NSCLC) expressing the programmed cell-death ligand 1 (PD-L1) protein responded better to ini

COPENHAGEN—Longer progression free survival (PFS) was achieved in patients with ALK-rearranged non-small cell lung cancer (NSCLC) previously treated with crizotinib randomised to treatment with the se

The Audio Journal of Oncology Reporting from the 2016 Congress of the European Society of Medical Oncology COPENHAGEN—The anti-PD-L1 (programmed cell death ligand-1) immunotherapy agent atezolizumab e

COPENAGEN—Adding the PD-1 (programmed cell death protein 1) antibody pembrolizumab to standard first-line chemotherapy with carboplatin and pemetrexed for previously-untreated patients with advanced n

COPENHAGEN—In a phase I study reported at the 2016 congress of the European Society for Medical Oncology (ESMO) six out of 15 patients with resectable early non-small cell lung cancer had “major

Audio Journal of Oncology COPENHAGEN, Denmark—In a phase 1b study patients with previously untreated stage IV pancreatic cancer responded or derived “clinical benefit” from a regimen in wh

COPENHAGEN, Denmark—Marked prolongation of progression free survival (PFS) in all groups of patients with platinum-sensitive recurrent ovarian cancer was reported at the European Society for Medical O

DESCRIPTION COPENHAGEN, Denmark—The efficacy of endocrine therapy in breast cancer was improved—in the MONALEESA-2 study—by the addition of the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib t

COPENHAGEN, Denmark—Checkpoint inhibition prolonged life when used as adjuvant therapy among patients with fully resected stage III malignant melanoma in the EORTC 18071 randomized phase III compariso

David Cameron Martine Piccart Eric Van Cutsem Jim Cassidy Volker Heinemann Lapatinib Better for Patients with HER2+ Refractory Breast Cancer Pre-treated with Chemotherapy and Trastuzumab REFERENCE: ES

Reporting from: – San Antonio Breast Cancer Symposium, December 8-11, 2004 – European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna In this edition: Raimund J

Reporting from: – Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego – Chemotherapy Foundation Symposium, November 10-13 2004, New York – European So

Reporting from: – European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna – Journal of Clinical Oncology – New England Journal of Medicine – Lancet